{"id":4480,"date":"2025-03-31T18:12:09","date_gmt":"2025-03-31T18:12:09","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/zoledronic-acid-txt\/"},"modified":"2025-03-31T18:12:09","modified_gmt":"2025-03-31T18:12:09","slug":"zoledronic-acid-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/zoledronic-acid-txt\/","title":{"rendered":"Zoledronic acid.txt"},"content":{"rendered":"

CLINICAL USE <\/H3> Hypercalcaemia of malignancy Reduction of bone damage in advanced malignancies Paget\u2019s disease

DOSE IN NORMAL RENAL FUNCTION <\/H3> Hypercalcaemia of malignancy: 4 mg as a single dose Reduction of bone damage in advanced malignancies: 4 mg every 3\u20134 weeks Paget\u2019s disease: 5 mg as a single dose

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : 272.1 <\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : 56 <\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 39 +\/\u2013 16 <\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp : 6.1\u201310.8 litres <\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp : 146\/Increased

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4> >60 Dose as in normal renal function 50\u201360 3.5 mg 40\u201349 3.3 mg 30\u201339 3 mg <29 Use 3 mg with caution if benefit outweighs risk

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp: Unknown dialysability. Dose as in GFR<29 mL\/min <\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : Unknown dialysability. Dose as in GFR<29 mL\/min
  • HDF\/high flux &nbsp : Unknown dialysability. Dose as in GFR<29 mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp: Unknown dialysability. Dose as in GFR=30\u201339 mL\/min

    IMPORTANT DRUG INTERACTIONS <\/H3> Potentially hazardous interactions with other drugs Other nephrotoxic drugs: use with caution as can enhance nephrotoxicity

    ADMINISTRATION <\/H3>

    Reconstition<\/H4> Add 5 mL of water for injection to each 4 mg vial

    Route <\/H4> IV

    Rate of Administration <\/H4> 15 minutes

    Comments<\/H4> Add to 100 mL sodium chloride 0.9% or glucose 5% Reconstituted solutions are stable for 24 hours at room temperature

    OTHER INFORMATION <\/H4> Also administer a calcium supplement of 500 mg daily plus 400 IU of vitamin D daily Increased risk of renal deterioration if GFR <10 mL\/min \u2013 measure creatinine while on zoledronic acid Increased risk of renal impairment in older patients, smokers, previous pamidronate therapy and renal failure. (Oh WK, Proctor K, Nakabayashi M. The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid. Cancer. 2007, Mar 15; 109(6): 1090\u20136.) Incidence of acute renal failure is 10.7%, usually due to acute tubular necrosis. (Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med. 2003; 349(17): 1679\u20139.) Increased risk of renal failure if use 8 mg May cause osteonecrosis of the jaw .
    \n","protected":false},"excerpt":{"rendered":"

    CLINICAL USE Hypercalcaemia of malignancy Reduction of bone damage in<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4480","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4480","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4480"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4480\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4480"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4480"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4480"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}